| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | ABCC10 |
| Uniprot No | Q5T3U5 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 全长 |
| 氨基酸序列 | full |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于ABCC10重组蛋白的3篇代表性文献摘要概览：
---
1. **文献名称**: "Expression and Purification of Recombinant ABCC10 in Insect Cells for Functional Analysis"
**作者**: Smith J, et al.
**摘要**: 该研究通过杆状病毒-昆虫细胞系统成功表达并纯化了ABCC10重组蛋白，验证了其作为药物外排泵的功能，并发现其与紫杉醇等化疗药物的耐药性相关。
---
2. **文献名称**: "Structural Insights into ABCC10/MRP7 through Recombinant Protein Crystallography"
**作者**: Wang L, et al.
**摘要**: 作者利用重组ABCC10蛋白进行X射线晶体学研究，解析了其跨膜结构域的三维构象，揭示了特定氨基酸残基在底物识别和ATP结合中的关键作用。
---
3. **文献名称**: "Functional Characterization of ABCC10 Recombinant Protein in Anticancer Drug Transport"
**作者**: Chen R, et al.
**摘要**: 研究通过体外膜囊泡实验证明，重组ABCC10蛋白可主动外排吉西他滨和埃坡霉素，提示其在肿瘤多药耐药中的调控机制，为靶向抑制剂开发提供依据。
---
注：以上为示例性内容，实际文献需通过PubMed/Google Scholar等数据库检索关键词(如ABCC10 recombinant protein、MRP7 expression)。建议结合具体研究领域筛选近年高影响力论文。
**Background of ABCC10 Recombinant Protein**
ABCC10. also known as multidrug resistance-associated protein 7 (MRP7), is a member of the ATP-binding cassette (ABC) transporter superfamily. These proteins utilize ATP hydrolysis to transport various substrates, including endogenous metabolites, lipids, and xenobiotics, across cellular membranes. ABCC10 is primarily localized to the plasma membrane and plays a significant role in multidrug resistance (MDR) by effluxing chemotherapeutic agents, antiviral drugs, and other xenobiotics, thereby reducing their intracellular concentrations.
Structurally, ABCC10 consists of two transmembrane domains (TMDs) and two nucleotide-binding domains (NBDs), characteristic of ABC transporters. Its substrate specificity includes taxanes (e.g., paclitaxel), antimetabolites (e.g., gemcitabine), and nucleoside analogs (e.g., tenofovir), linking it to resistance in cancers and viral therapies. Recombinant ABCC10 protein is engineered using heterologous expression systems (e.g., insect or mammalian cells) to produce functional, purified protein for in vitro studies.
Research on recombinant ABCC10 focuses on elucidating its transport mechanisms, substrate interactions, and role in MDR. It serves as a tool for screening inhibitors to overcome drug resistance, studying structure-function relationships, and developing targeted therapies. Additionally, ABCC10’s involvement in physiological processes, such as lipid homeostasis and cellular detoxification, highlights its broader biomedical relevance. Challenges remain in fully characterizing its regulatory pathways and tissue-specific functions. Advances in structural biology and drug discovery platforms using recombinant ABCC10 may pave the way for novel therapeutic strategies to counteract resistance and improve treatment outcomes.
×
